Abstract
Due to the recommendations in the urological guidelines to perform nephron-sparing surgery in patients with organ-confined renal cell carcinoma (RCC), the customary therapy regimen changed, but it is not well studied yet whether partial nephrectomy (PN) especially in the elderly is beneficial. From 2000 to 2015, 3,592 patients from 7 clinics undergoing surgery in RCC were identified; 2,323 had T1 tumours. We retrospectively compared the overall survival benefit of patients with T1 RCC who underwent either PN or radical nephrectomy (RN) and studied effects of age and gender. Results: In T1 RCC, PN was beneficial in male patients (p = 0.0006) independent of age, especially in those men ≤75 years of age (p = 0.0005); but PN was not beneficial for female patients (p = 0.0629) regardless of age and male patients older than 75 years (p = 0.736). The OS of female patients after RN and male patients after PN is the same, regardless of age. A life expectancy of more than 45 months at least is necessary to experience an overall survival benefit after PN. Conclusions: There should be harder proven indications for PN in female patients and especially in all patients older than 75 years, particularly with regard to perioperative risk factors.
Journal Section:
Editor's choice
References
1.
Janzen NK, Kim HL, Figlin RA, Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 843–852.
[PubMed]
2.
Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168: 2395–2400.
[PubMed]
3.
Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS: Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urology 2005; 174: 466–472; discussion 472; quiz 801.
[PubMed]
4.
Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, Cindolo L, Han KR, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Mulders PF, Belldegrun AS: Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 2004; 171: 2181–2185, quiz 2435.
[PubMed]
5.
Zini L, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Antebi E, Saad F, Patard JJ, Montorsi F, Karakiewicz PI: Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer 2009; 115: 1465–1471.
[PubMed]
6.
Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H: Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000; 75: 1236–1242.
[PubMed]
7.
Sun M, Trinh QD, Bianchi M, Hansen J, Hanna N, Abdollah F, Shariat SF, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI: A non-cancer-related survival benefit is associated with partial nephrectomy. Eur Urol 2012; 61: 725–731.
[PubMed]
8.
Ljungberg B (Chair, Bex A (Vice-chair), Canfield S, Dabestani S (Guidelines Associate), Giles RH (Patient Advocate), Hofmann F (Guidelines Associate), Hora M, Kuczyk MA, Lam T, Marconi L (Guidelines Associate), Merseburger AS, Powles T, Staehler M, Volpe A: Guidelines on renal cell carcinoma. Eur Assoc Urol 2015
9.
Ljungberg B (Chair), Bex A (Vice-chair), Canfield S, Giles RH (Patient Organisation Representative), Hora M, Kuczyk MA, Lam T, Merseburger AS, Powles T, Staehler M, Volpe A, Guidelines Associates: Dabestani S, SF-PM, Hofmann F, Marconi L, Tahbaz R: EAU Guidelines on Renal Cell Carcinoma (limited text update march 2016), 2016.
10.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 1.0, 2015, AWMF Registernummer: 043/017OL, http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html (Zugriff am: TT.MM.JJJJ).
11.
Sun MB, Bianchi M, Trinh QD, Hansen J, Abdollah F, Hanna N, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI: Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities. BJU Int 2012; 111: 67–73.
[PubMed]
12.
Lane BR, Abouassaly R, Gao T, Weight CJ, Hernandez AV, Larson BT, Kaouk JH, Gill IS, Campbell SC: Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 2010; 116: 3119–3126.
[PubMed]
13.
Tan HJ, Norton EC, Ye Z, Hafez KS, Gore JL, Miller DC: Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA 2012; 307: 1629–1635.
[PubMed]
14.
Sun M, Abdollah F, Bianchi M, Trinh Q-D, Jeldres C, Thuret R, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI: Treatment management of small renal masses in the 21st century: a paradigm shift. Ann Surg Oncol 2012; 19: 2380–2387.
[PubMed]
15.
Zini L, Patard JJ, Capitanio U, Mejean A, Villers A, de La Taille A, Ficarra V, Crepel M, Bertini R, Salomon L, Verhoest G, Perrotte P, Bensalah K, Arjane P, Biserte J, Montorsi F, Karakiewicz P: The use of partial nephrectomy in european tertiary care centers. Eur J Surg Oncol 2009; 35: 636–642.
[PubMed]
16.
Dulabon LM, Lowrance WT, Russo P, Huang WC: Trends in renal tumor surgery delivery within the United States. Cancer 2010; 116: 2316–2321.
[PubMed]
17.
Dash A, Vickers AJ, Schachter LR, Bach AM, Snyder ME, Russo P: Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4–7 cm. BJU Int 2006; 97: 939–945.
[PubMed]
18.
Huang WC, Elkin EB, Levey AS, Jang TL, Russo P: Partial nephrectomy versus radical nephrectomy in patients with small renal tumors–is there a difference in mortality and cardiovascular outcomes? J Urol 2009; 181: 55–61; discussion 61–52.
[PubMed]
19.
Miller DC, Schonlau M, Litwin MS, Lai J, Saigal CS: Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer 2008; 112: 511–520.
[PubMed]
20.
Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, Scardino PT, Russo P: Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7: 735–740.
[PubMed]
21.
Tobert CM, Riedinger CB, Lane BR: Do we know (or just believe) that partial nephrectomy leads to better survival than radical nephrectomy for renal cancer. World J Urol 2014; 32: 573–579.
[PubMed]
22.
Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Colombel M, Klotz L, Skinner E, Keane T, Marreaud S, Collette S, Sylvester R: A prospective, randomised eortc intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urolgy 2011; 59: 543–552.
[PubMed]
23.
Tan HJ, Wolf JS Jr, Ye Z, Hafez KS, Miller DC: Population level assessment of hospital based outcomes following laparoscopic versus open partial nephrectomy during the adoption of minimally invasive surgery. J Urol 2014; 191: 1231–1237.
[PubMed]
24.
Shah PH, Moreira DM, Patel VR, Gaunay G, George AK, Alom M, Kozel Z, Yaskiv O, Hall SJ, Schwartz MJ, Vira MA, Richstone L, Kavoussi LR: Partial nephrectomy is associated with higher risk of relapse compared with radical nephrectomy for clinical stage T1 renal cell carcinoma pathologically up staged to T3a. J Urol 2017; pii: S0022-5347(17)35379-X.
[PubMed]
25.
Shekarriz B, Upadhyay J, Shekarriz H, de Assis Mendes Goes F Jr, Bianco FJ, Tiguert R, Gheiler E, Wood DP Jr: Comparison of costs and complications of radical and partial nephrectomy for treatment of localized renal cell carcinoma. Urology 2002; 59: 211–215.
[PubMed]
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.
